Scarica l'app Stockscreener
13.51
0.37%
0.05
Dopo l'orario di chiusura:
13.51
Precedente Chiudi:
$13.46
Aprire:
$13.52
Volume 24 ore:
357.41K
Relative Volume:
0.80
Capitalizzazione di mercato:
$939.98M
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
-8.947
EPS:
-1.51
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
-5.66%
1M Prestazione:
+8.34%
6M Prestazione:
-7.53%
1 anno Prestazione:
+27.45%
Intervallo 1D:
$13.03
$13.58
Intervallo di 1 settimana:
$13.03
$14.46
Portata 52W:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
13.51 | 1.01B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Analyzing Zymeworks Inc. with risk reward ratio chartsFree Daily Top Performing Stock Insights - Newser
How to read the order book for Zymeworks Inc.Entry Signal Generator with Risk Metrics - Newser
Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance - MSN
How did ZYME's Q1 2025 EPS forecast compare to past trends? - AInvest
What factors could impact ZYME's future EPS growth? - AInvest
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate - wahanariau.com
Zymeworks’ second ADC with TOPO1 inhibitor payload to enter clinic in US - BioWorld MedTech
Zymeworks’ ZW251 Receives FDA Clearance for Clinical Trials in Liver Cancer - TipRanks
FDA clears Zymeworks’ IND for liver cancer drug candidate ZW251 By Investing.com - Investing.com South Africa
Zymeworks Inc. Advances ZW251 into Clinical Development for Hepatocellular Carcinoma Following IND Clearance from FDA - Quiver Quantitative
FDA Green Lights Revolutionary First-in-Class Liver Cancer Drug: Zymeworks Advances New Treatment - Stock Titan
When is Zymeworks Inc. stock expected to show significant growthDiscover high-impact stocks for growth - jammulinksnews.com
What catalysts could drive Zymeworks Inc. stock higher in 2025Explosive trading growth - jammulinksnews.com
How does Zymeworks Inc. compare to its industry peersOutstanding trading profits - jammulinksnews.com
How volatile is Zymeworks Inc. stock compared to the marketExponential return rates - jammulinksnews.com
Does Zymeworks Inc. stock perform well during market downturnsCapitalize on fast-growing stocks today - jammulinksnews.com
What are analysts’ price targets for Zymeworks Inc. in the next 12 monthsFree Stock Index Interpretation - jammulinksnews.com
What is Zymeworks Inc. company’s growth strategyGame-changing returns - jammulinksnews.com
Will Zymeworks Inc. stock benefit from AI tech trendsFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Zymeworks Inc. stockRapid wealth multiplication - Autocar Professional
Zymeworks Inc.'s (NASDAQ:ZYME) Shareholders Might Be Looking For Exit - 富途牛牛
What drives Zymeworks Inc. stock priceFree Market Dynamics Reports - Autocar Professional
Is Zymeworks Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Arizona State Retirement System - Defense World
Zymeworks Announces Pricing of $100.0 Million Public Offering - Finance Monthly
Zymeworks Inc. Stock Analysis and ForecastTremendous gains - jammulinksnews.com
Teacher Retirement System of Texas Cuts Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains? - MSN
Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences - The Globe and Mail
Zymeworks to Report Second Quarter 2025 Financial Results and Ho - GuruFocus
Zymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025 - Nasdaq
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.28%
2.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):